Episode 3 • Steve Bell on Exploring Endovascular Robots and The Market

Steve and Joe discuss the emerging market of endovascular robotics and how it sets up to be a bigger market than soft tissue robotics and enabled by quicker development times, less cost, and more acquirers in the market.

Released on: February 22, 2024 at 12:55 pm EST
Transcript

Speaker 1 [00:00:08] Joe Mullings from 160 studios back together with Steve, Val, Steve. Good to see you, man.

Speaker 2 [00:00:14] Hey, great to see you.

Speaker 1 [00:00:15] I, I got a lot of fantastic feedback from our last session. Our overview of soft tissue robotics. So I think you and I have agreed that we we should. Think out loud together at all. The emerging categories are robotics coming out. So what do you think?

Speaker 2 [00:00:33] Yeah. I’m game for that. That’s good. Yeah. And I got great feedback too. And they love the format, by the way. They love the format of your your podcast. So they’re really, really complimentary about the format. So. Great. Well, Roland Yeah.

Speaker 1 [00:00:44] Well, the partnership here makes it super easy, you know, both being educated, we were chatting before we went online is the amount of inbound questions and sort of comments that we get around where is robotics going next is certainly exciting and it’s where the investment dollars are going, technology’s going and I think the outcomes for the patients as well, Steve But I think today we wanted to talk about endovascular robotics and seems to be an underappreciated category. So I know you’ve done a little thinking on that. So where do you want to start?

Speaker 2 [00:01:16] Yeah, so I mean, it’s been an area that. There’s been a lot of dabbling in early on and some companies been out there with endovascular robots. And I was involved a lot with the vascular work in a previous startup, California. And it always felt to me like there was a. There was a need to be in there. And it’s actually been especially over the last couple of weeks when people been asking me, where are the companies going? What are they going to do? Where do they go next? They want to get multiple platforms where they go, you know, soft tissue, laparoscopic bronchial renal robots. And then. Can you look at it all? You start thinking to yourself, this is like a multibillion dollar opportunity in an end to vascular. So it gets a bit natural.

Speaker 1 [00:02:03] Yeah, Yeah. And and it sets up well for robotics because I think in the U.S. alone, there are 5 million procedures when you look at neuro peripheral, and cardiac. So you know the procedures there, the. The intention of a robot is to continue to do the same motion over and over and over, even in a master slave environment. Right. So, yeah. So when you think about these interventionalists having to use their fingers in a wire and all feel at all touch to get to through a torturous sort of anatomy, I just, you know, you scratch your head going, How come we haven’t gotten traction there yet. Cavendish tried early on in but you know first movers a lot of times always have a challenge there.

Speaker 2 [00:02:54] Yeah yeah This it’s difficult as well. And also, you know, I think there’s a lot of learnings that you get as you go into this. You know what people really want Whenever you’re a first mover, you’ve got to make some assumptions of what you think you’re bringing to the table. And maybe with Corinne, this on the on the cardiac side, they didn’t bring quite as much for the patient as they thought they were going to bring, and they thought it would bring in a lot for the physician. And maybe that wasn’t compelling enough for the whole picture to to to make it work. But I think there’s a lot of learnings that have come from that. And that’s why I think it’s going to be an interesting time because a lot of technology change is going to change as well.

Speaker 1 [00:03:35] Yeah. The lessons learned, you bring up a really interesting point. There’s a there’s an incubator out there that I have a lot of respect for. And the founder said to me, You know what I do, Joe? When I pick a technology to go after, I don’t go after something that I have to create a market. I just don’t want to have to get enough wind in my sails to do that. What I want to go after is a mass market that already has a player or two in it, and I can look at that and say, I could make that tremendously better. I can have better outcomes, better price point, easier for the team and the user and outcomes for the patient. And then I want somebody else to look at what I put to the market and say, You know what? That’s too good. Let’s go find something else to compete against. And I think the in the vascular robotics space sets up for that because right now and correct me if I’m wrong, Steve, but right now you really only have, I’d say two, maybe three acquirers of soft tissue robotic platforms. You’ve got the two obvious J and J and Big Tronic, and then you’ve got potentially Stryker, I’ve heard, been sniffing around in there.

Speaker 2 [00:04:41] Yeah, yeah. But beyond beyond that, you know. It’s not really one of the big strategics that would either have the horsepower or the infrastructure to take it on and actually do something good with it. So, yeah, it’s very limited, very limited. But it is different in the vascular.

Speaker 1 [00:04:59] Yes. And the vascular, you know, I think you and I went through it. You’ve got BMC, certainly Medtronic, Edwards, Abbott, Stryker, Becton, Dickinson, Siemens, GE, like one after another after another. And there’s an argument to be said that you can use that robotic platform for, again, neuro peripheral and cardiovascular.

Speaker 2 [00:05:22] Yes. Yes. And again, I think. Where for me, the excitement here as well as you starting to get a confluence of technologies that are coming together that can improve on what we’ve got. You know, again, I think one of the one of the issues that you have in early days when you do any kind of robotics is you’re you’re trying to just mimic what the physician does. Okay. So rotate a wire, push a wire, push your catheter, pull a catheter. Okay. And they they are maneuvers that they do today because you can’t reach inside and manipulate the tip with your fingers. So the natural fallback is I, I create a system that is really just trying to mimic what the physician is doing today. Well areas where I think we we’ve got now and again I look at companies like Intuitive and I look at Auris and I look at the technologies in there for catheter manipulation, tip manipulation, navigation. And you can use a lot more computing power now to lay down pathways to the vasculature. So my brain is sort of looking at this and saying, I think this is going to be some of these technologies as they come into these catheters technologies. I think some of the magnetic guidance is quite interesting as well in terms of moving the tip through magnetic cones, but different ways of manipulating the tips that you get easier, more, more accurate and more repeatable access. I mean, that’s where I think the robot can really, really, really help in this.

Speaker 1 [00:06:56] I’ve seen some of those technologies using the magnet to control that sort of distal end. And at MIT, he’s got a clever robot. And you were chatting about one when we were speaking earlier in the week. You know, but but I also think about where does this robot exist and what kind of footprint do I already have in that room if I especially if I’m looking at the migration of some of these produce procedures going to an ASC. So in most of them I’ve got to have big ion on the imaging side. Yeah, right. I’ve got to have other large carts or fixed systems in there. And then I’ve got a team in there and now I’m curious if I. If I add another form factor in there that doesn’t take all that into consideration. And when I think about a magnetic driven platform, I do need a substantial amount of mass and form factor in order to drive that catheter or guidewire to where I want to get it.

Speaker 2 [00:08:00] Yeah, I think that is so it’s not dissimilar to the soft tissue robotics, the lot, the challenges you have in places like ACS, the same challenges are completely mirrored. Depends whether you tend to vascular or you’re doing soft tissue and, you know, amount of hardware, size of hardware. And personnel is another one that is very interesting. It’s, you know, can you now use some of these technologies to reduce the number of personnel required for some of these interventions? Because I think that’s an important factor in when you’re trying to take it to a lower acuity site of care.

Speaker 1 [00:08:34] And you bring up a really good point because as we go to these bases, it’s going to be interesting to see.

Speaker 2 [00:08:41] How.

Speaker 1 [00:08:42] They staff those because the economics in an ASC are tremendously different. What is interesting though, is the reimbursement in the in the vascular space sits at a higher level than a general surgery procedure. So the math changes and empowers in a totally different way. If you’re looking at 5 million procedures each year, right, to give, to give a reference point. Last year, I think Intuitive did 1.8 million procedures. Yes. So so you know, and what are they own 75% of that general surgery soft tissue market so you’ve got 5 million procedures and you’ve got a 15 to $18,000 reimbursement strategy. And you probably have a less complex robot from a cost per perspective servicing and maintenance perspective. And you can very clearly probably remove at least one headcount from the room.

Speaker 2 [00:09:38] Yeah. So it starts stacking up and again. What I’m looking at was that air is a medical device. I’m looking for the drivers. You know, what’s what’s the big driver? What’s what’s the thing that’s going to pull If you’ve got to push the boulder up the hill? You know, it’s really hard to get some of these technologies to switch across if it’s if it’s just everything is an uphill push. But if you’ve got some real pull coming from the market because you’ve got, you know, favorable reimbursement for it, you’ve got the desire to take it to a different place of care. If you can reduce staff, that’s and that is a I think. It’s not just about producing stuff. The stuff availability in some parts of the world is just like so difficult to deal with at the minute. So you call all those things that just help the institution, help the hospital and are in their favor. Then I think you’ll see a much faster adoption of that technology to pull through of that technology. I think that’s why it is a really exciting space.

Speaker 1 [00:10:35] Also, one of the things that I look at when I think about it in the vascular space, when we know the form factor in a minute, because there’s platforms out there like microbes. And I want to talk about microbes versus a large platform like perhaps a Kirin. This is a as a as a placeholder or robo calf. But. When when I when I think about that in the vascular, especially on the neuro side of things, is that set up time is going to be really imperative in regards to certain procedures where time is of essence. And and we were looking at I was looking at one yesterday and the the the interventionalists who was demonstrating it had showed that they do a dry run before they start the procedure just in case the robot goes down to swap out the cassette to then come in and then make sure we can do it manually. And that adds probably another 7 to 10 minutes, up to 15 minutes to the setup time. And so you’ve got to look over time as brain in those areas. What what and how do you address that unnecessary or critical setup time.

Speaker 2 [00:11:43] Yeah. And again, when I look at the systems that are currently on the market there today, I think they’re a good first attempt. But I think some of those things that you say, which is this, you know, litical speed of setup time, every second counts. And anything that can be done with the systems I’m not familiar with to many of the new systems are know like really under the radar at the minute but I will be digging in. I think that they have to go. One of the things they’ve got to do is that speed of self speed of tear down reduction of staff. Yeah. Cost as well. It will be import, it will be important. You can’t just have unlimited money going at this. So I think I think there’s a lot of things that if I was in a startup space at the minute, I think I have a really good mapped out needs chart that I’d go after.

Speaker 1 [00:12:33] And then looking the nice thing is, is we’ve had the chance to watch the market, at least from an analog perspective. Watch how intuitive sort of really stumbled their way through their early years to where the market is right now and clearly market dominant. And then we’ve watched the fast followers try to go after that in a similar fashion. So there were lessons learned along the way that. To your point, you just pointed out, it’s not always about the. Performance of the robot as the primary driver. It’s the economics for change management, which is supercritical. I mean that. Yeah. And then how long does it take me to learn on this robot? That’s going to be really important? Because on one side, it really does accelerate the competency curve on on early stage surgeons or interventionalists. It really accelerates it. But how long is it going to take for me to learn how to use this system, this robot? And this leads me into the form factors. You could look at the career in this type of platform. You could look at the Microbots platform, which is a fully disposable robot. Yeah, that. I’m guessing that that little joystick console may cost $1,000 and you tossing it out. And from what I understand is they’re going to be able to use standard wires in order to drive that. So that that then becomes a really interesting economic sort of equation to to unplug.

Speaker 2 [00:14:07] Yeah, I think the interest in her own team. I spoke to them in the past and. Yeah. I find interest in the concept of a disposable. When I first heard it, I was like, Seriously? But then when you actually look at it, it’s not as crazy as you first think. You think to yourself, as you were talking about, you know, if it can mean that you’ve got a much smaller form factor, if you don’t have to deal with things like the same sort of cassettes and all that kind of stuff in the set up and it can be faster and faster to intervention. You start thinking, Actually, maybe it’s not as crazy as I first thought. So, yeah, I agree.

Speaker 1 [00:14:42] Yeah. Again, and I’m going to be at LSI in March and we’re going to have a panel where we’re going to talk about robotics, the right robot at the right time, in the right scenario for the right patient. And I think about a mike robot as one of those, not the final solution that might not be. And it won’t be your end, the vascular robot, but it will be in the suite of products that you’ll take into consideration based upon get me off that shelf patient coming in. Let’s use a mike robot system. Let’s roll. Right. That that’s where I think we’re going to start to see more in the in the vascular space than anybody else. I’m curious what you say about this. Do you think Gary and the team at Intuitive don’t already have these going on in their skunkworks?

Speaker 2 [00:15:31] So. Why was I very curious? By the end of the space when I was looking at this was because if you look at, you know, it’s got iron, right? That’s a catheter driven system. You’ve got Monarch, which is a Catholic driven system, and it’s not a huge leap of technology to be able to jump from what they’re doing today in the long to what, you know, doing that as an end to vascular robot and. You know, the end of asking space is potential to an 8 billion space. You can’t really ignore it. Now, whether they’ll ever get into it or whether JJ or or Intuitive will actually ever get into that space. They’ve got to be looking at it, right? You’ve got to be your engineers have got to say we’d have to modify X, Y, and Z. But, you know, technically we’ve got the ability to do this. So I’ll be I’ll be surprised if they’re not got some kind of program within their that’s already looking at how do you adapt the technology in-house to be able to do that?

Speaker 1 [00:16:34] Well, I think you’re on to something there because in order for Monarch to get over the line, they needed to pick up the IP from Hanson. And Hanson was used to drive that sort of catheter technology, which originally was focused not in the pulmonary space. So I think that sits in there now. Do I think that JNJ has the internal team to drive that? I don’t think so, and I don’t think they should waste their calories or R&D dollars on that. This is where I believe you’re going to have the smaller companies develop these technologies. And unless you’re a digital native and you spend all your money and all your time, you. I think I think Gary said a while back. I’m a I’m a surgical company. I’m not a robotic company. But everything they do is going to be driven by robotics. So to your point, you can’t you can’t disregard $1 billion market where there are, again, no primary players right now who are in the market.

Speaker 2 [00:17:38] So it’s interesting when you say about in choosing more surgical company. So as most people point out, it used to be called Intuitive Surgical and now it is called intuitive. And they very actually I wouldn’t say stealthily, but they they removed the surgical. And again, for me, that sort of as a marketing strategist tells me that, you know, trying to not be just surgical and of course ion is not considered surgical, but it opens up a spectrum of other areas you can go into where. Where the robot can be at the center of it. Your digital ecosystems can be at the center of it, and you can just leverage all of that infrastructure that you have to go into big open spaces and, you know, and do really good things there. So I think they would do that. But there’s an interesting thing and I’d like to get your opinion on as well, which is. So let’s you said about change. So they’ve got they’ve got their monic technology. I think what would be sensible for some of these companies to do is to say to a small startup here, how about it? Take the core technology. We will going to grant this to you, but you guys going to work out how you turn that into an end to vascular robot. I think that that in my mind could be a methodology to get that rapid innovation which the small companies are good at with a really focused purpose, which is you and build that and it comes back in when it’s ready.

Speaker 1 [00:19:10] Yeah. And that’s that build to buy model that I think we’re going to see more of as long as the, you know, Big Blue Medtronic and Big Red J and J can get over there if not built here. You don’t understand us. You don’t know how to work that through the process. And it’s not a knock. It’s a fact. You know, it’s clearly evidenced every day. But I do believe you’ve got to put that you’ve got to create an entire and they’re trying to do that. JNJ is trying to do that right out February right now. But the Martin’s leading that who’s a wonderful man. But you still have when I chat with them and I have really intimate conversations with them, you can still feel that lockstep walk of this is how we do things. And if you continue with this is how we do things. You get the same things.

Speaker 2 [00:20:07] Yeah. Yeah. I mean, I definitely felt. But there’s a shift in that company. You know, I’ve seen that shift with the recent changes change in MedTech. I’m very hopeful, actually. I’m actually very hopeful that change is working. I mean, I’ve seen how they’ve done with the Abiomed deal. That is the right way to do it. The way that on that deal, I’m actually very impressed by the way that they’ve done that and they’re seeing the rewards of it. Right. You know, they’re already seeing the rewards of that. And again, with the Abiomed going in that space, you know, now they used to have Cordis and they used to have a neuro company as well. We divested out of those. But maybe now is the time for them to think about how do they get back into those markets in a meaningful way.

Speaker 1 [00:20:53] And that’ll take the leadership. Steve, I’ve been at this 32 years. Here’s what happens is. And I agree with you. I like what he’s doing a lot. A lot. I just want to make sure they remain disciplined. You know, from Braveheart. Hold, hold, hold. Because once that becomes or continues to evolve to the jewel in the crown, let’s use ABM. It is that.

Speaker 2 [00:21:18] Yeah.

Speaker 1 [00:21:19] People want to manage their careers and their success through the entity. Rather than fixate on the entity and culturally Mike model built that as patient. Product. Self. And he really lived that. You can go back and see a recent podcast. Mike was in Studio one. And what I always worry about, I don’t doubt that. Jay a corporation puts the patient first. What I worry about are people who are 20 to 30 years into their career have been locked into Jay and Jay for a long time and now see the pretty new pretty girl at the dance and now want to start justifiably so getting on that and then influencing what happens in there, which means bringing in the SLPs in the mindset of the big corporation. So the executive leaders are going to really have to create a wall around that in order for that innovation to continue to be accelerated and not dilute what got us there in the first place, Right? It’s yeah, it’s a little like Florida, and we get nervous down here in Florida that all the New Yorkers are moving down here and now they’re trying to change it into New York because that’s what they’re used to. And we’re like, no, no, no. If you’re coming down to Florida, you’re coming down here because how it is today, don’t try and change it to New York because you’re from New York, like live our Florida life. And that is a little bit like, you know, when you get these big organizations by these unbelievable companies, they, by design, can’t help themselves. And what corporate leadership has to do is design it so that cannot be infiltrated.

Speaker 2 [00:23:03] Yeah, no, I agree. And it does amaze me so much how sometimes it’s misunderstood the power and the drive of culture within an organization. And if you strip out that culture, you rip the heart out the company. I’ve seen it so many times, you know, with with acquisitions over the years see it again. I think the small smart companies in the future will that they will understand they’re not just buying metal and plastic. They’re buying human beings and culture in the middle of that. They’re the things that have made it really successful. So yeah, I’m looking forward to see how that pans out over the years.

Speaker 1 [00:23:41] Yeah. I want to wrap back around to the in the vascular space for a second. We’ve talked about therapeutic the for most of the conversation earlier. There are a couple of platforms out there right now that are diagnostic robotic platforms in nature and especially in the interventional cardiology and structural heart space where if you think about the unlock in that market, it’s been imaging. And so now you’ve got a you know, you’ve got a a team typically in that, you know, cath lab suite of advanced that has to go on all the time. And the Interventionalists has their relationship there. But I believe that under development right now are some very interesting self-driven by the interventionalists diagnostic robotic imaging technologies that will make it through the FDA. In relative terms. Cleaner and easier. And I think that you’re going to start to see an entire category of diagnostic, robotic, sort of driven systems that have the same baseline as an in the vascular therapeutic delivery mechanism. Only now we will have imaging into it and that that’s really critical because that ties into another category, Steve, that’s growing very quickly is precision guided therapies, I guess. You know, so there’s a company out there called On Target and they’ve got a product called Site of Lux and and Stryker is partnering up with them. And what they’re able to do is take a molecule and put it into a cancer cell and it lights up. It allows the surgeon then to go in. So think about big ion, the guys, the Philips, the Siemens that you can go pre-op imaging and then you think about the therapeutic side downrange and all of those, whether it’s Stryker, Boston PSI, Olympus, whatever it is. And now in the middle, you can light up what you’re trying to get into and use as a therapy and then drive into vascular robotics towards that. You’re going to have a very interesting solution coming up soon.

Speaker 2 [00:26:01] Yeah, I think that. Across the whole spectrum of health care. Precision targeting is the targeting systems in the perioperative phase that are going to become really interesting. And again, I can go back to intuitive. I think that I own they’re going to use that as a guidance map for when you come side to go and make sure that instead of taking a whole wedge out now, you can have super precision and take a bleb out. You know, you’re able to light up just that small area. And the same will be true in endovascular that you’ll be able to have a precision guided diagnostic that will then allow either delivery or targeting, or it will allow you to be much more precise in your delivery of therapy and therefore have less collateral damage. Less collateral effects. Yeah, that is definitely coming. And I think, again, it’s always when there’s a confluence of technology that allows it, it’s the robotic technology is improving, it’s miniaturizing, it’s getting smaller, the targeting technologies are improving daily. And then the that the smarts behind the AI and the compute power that you need to make these things really effective are coming. So you start getting this convergence of all these technologies that allow this to become more and more precise. So yeah, I think there’s a whole category there for sure.

Speaker 1 [00:27:16] Yep. And then final question as we wrap up, I want to ask you because you usually have some insights into these things more than the average bear, the Gen five intuitive release coming out, which I think I think we talked about this, they were clever because it’s just going to freeze the market until the end of the year. On anybody buying anything. Do you think that they’re going to introduce as an option an open console?

Speaker 2 [00:27:48] So I’ve speculated a little bit on this. You have to remember back in the day, they actually did have an open console back when they took Sousse. So so it’s not that strange to it. They made a strategic decision at the time and they felt that the the eye to hand coordination that you got with the periscope view was was the paradigm that they preferred. I think. It’s going to give me 1 or 2 things that he’s going to really entrench and dig their heels in and say, no, no, no. The periscope was the only way. Or they’re going to listen to the market. I can tell you more than half the market prefers an open console. Just we just hear it all day, every day that people prefer that. And what they’re trying to do at the minute is that a big piece of getting across to their full line of sight procedures that they’re after? You have to bring those laggard laparoscopy on board. You have to. So is one of the tools that you could do to that is for those that say, I will not stick my head into a pair. I am not sticking my head. I’ve done 25 years with an open screen. I want an open screen. I’m having an open screen. Do they fight that or do they say, okay, if we want to hit that 25% of surgeons that will never bring a cross without it, unless they have an open screen, then there is a chance that that could be an option. If you want an open screen, we will allow you to somehow use an open screen with our system. I don’t know. But I think. If they got out, loaned on any market research in the past year, which I’m sure they do every single day, there’s that there is a slice of the market that has to have an open screen to come across.

Speaker 1 [00:29:33] Yeah, I’m really curious. And if it comes out now in the June 5th, which may add a level of complexity they may not want to deal with with the FDA. But I was just curious what your thoughts are. So I’m going to get pinged on that. And I’m I’m I’m along the lines with you. I think they will have it as an option. I just don’t know if it’s going to be this year. So. Yeah, yeah, yeah. All right, my friend, as always, I enjoy the conversation and I will be looking forward to our next one.

Speaker 2 [00:30:00] Excellent. Thank you very much and have a great day. Take care.

Speaker 1 [00:30:03] Take care. I’m Joe Mullins. Untitled. Provocative and necessary conversations. Be well.

Previous Episode

Episode 2 • Mike Minogue on Leadership and Abiomed

Joe and Mike Minogue, the recent CEO of Abiomed which was sold to Johnson &...
Joe and Mike Minogue, the recent CEO of Abiomed which was sold to Johnson & Johnson for $16 billion discuss some of the principles and the mindset of how to build high performing teams and enable success.
Show more Show less
Read
Next Episode
Tony Blauer wrote the book on the Management of Fear in Combat Sports as well as violent encounters. His body of work is even more applicable in the business world. Joe and Tony discuss how fear management and the control of our emotions can be the difference maker in success and failure.

Episode 4 • Tony Blauer on Managing Fear in a Career

Tony Blauer wrote the book on the Management of Fear in Combat Sports as well...
Tony Blauer wrote the book on the Management of Fear in Combat Sports as well as violent encounters. His body of work is even more applicable in the business world. Joe and Tony discuss how fear management and the control of our emotions can be the difference maker in success and failure.
Show more Show less
Read
Released on:
The Untitled Podcast is designed to get you to think. Not what to think, but think. We cover subjects in healthtech, medtech, personal performance, and leadership.